Real-world dapagliflozin experience in patients with heart failure in United Kingdom. - EVOLUTION-HF

Study identifier:D169CR00001

ClinicalTrials.gov identifier:NCT05188144

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Early treatment of heart failure: a non-interventional observational study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF - UK)

Medical condition

heart failure

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

239

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 29 Nov 2021
Primary Completion Date: 02 Mar 2024
Study Completion Date: 02 Mar 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria